Novartis AG vs Abbvie Inc.
NVS vs ABBV — side-by-side comparison from reported financials. NVS leads 8, ABBV leads 4 of 12 comparable metrics.
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | NVS | ABBV |
|---|---|---|
| Price | $143.75 | $276.43 |
| Market cap | $273B | $488B |
| Revenue (TTM) | $56.7B | $64.4B |
| Revenue growth | +9.1% | +1.8% |
| Net margin | 24.7% | 9.8% |
| Free cash flow | $16.8B | $18.2B |
| Net cash (debt) | ($41.4B) | ($56.2B) |
| 1-year price return | +9.7% | +19.8% |
| P/E | 20.3 | 77.4 |
| P/E vs own history (cheap-side %) | 46% | 23% |
| Dividend yield | 3.49% | 2.45% |
| Return on equity | 30% | 96% |
| Altman Z-score | 3.50 | 2.33 |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 75,267 | 57,000 |
Full résumé-style profiles: NVS CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.